Chifeng Sailintai Pharmaceutical

Chifeng Sailintai Pharmaceutical is a specialized pharmaceutical company based in China that functions as the industrialization and manufacturing arm of the Sailintai Group. The company focuses on the development and production of innovative small molecule drugs, particularly targeted therapies for oncology and metabolic diseases. Its lead asset, CT-707, is a multi-kinase inhibitor targeting focal adhesion kinase (FAK) and is currently in Phase 2 clinical trials for ALK-positive non-small cell lung cancer. The company also maintains a robust early-stage pipeline including KRAS G12D and FGFR inhibitors. Chifeng Sailintai operates a large-scale manufacturing facility in Inner Mongolia that adheres to international GMP standards. Through its partnership with its R&D-focused parent company in Beijing, it bridges the gap between drug discovery and commercial-scale supply.